Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Arvinas Inc (ARVN)

Arvinas Inc (ARVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,371,654
  • Shares Outstanding, K 68,308
  • Annual Sales, $ 78,500 K
  • Annual Income, $ -367,300 K
  • 60-Month Beta 1.94
  • Price/Sales 29.84
  • Price/Cash Flow N/A
  • Price/Book 2.79
Trade ARVN with:

Options Overview Details

View History
  • Implied Volatility 64.29% ( +0.98%)
  • Historical Volatility 35.44%
  • IV Percentile 6%
  • IV Rank 12.53%
  • IV High 125.27% on 11/13/23
  • IV Low 55.56% on 09/19/23
  • Put/Call Vol Ratio 0.11
  • Today's Volume 460
  • Volume Avg (30-Day) 190
  • Put/Call OI Ratio 0.43
  • Today's Open Interest 5,963
  • Open Int (30-Day) 5,076

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -1.48
  • Number of Estimates 11
  • High Estimate -1.03
  • Low Estimate -2.42
  • Prior Year -1.54
  • Growth Rate Est. (year over year) +3.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
32.61 +6.47%
on 04/18/24
44.85 -22.59%
on 03/21/24
-7.84 (-18.42%)
since 03/19/24
3-Month
32.61 +6.47%
on 04/18/24
53.08 -34.59%
on 02/16/24
-1.70 (-4.67%)
since 01/19/24
52-Week
13.57 +155.86%
on 10/27/23
53.08 -34.59%
on 02/16/24
+7.02 (+25.34%)
since 04/19/23

Most Recent Stories

More News
How Recent Biotech Breakthroughs Are Changing the Fight Against Breast Cancer

USA News Group – More people are getting breast cancer this year. Around 300,000 women and 2,800 men will find out they have it. While 1 out of every 8 women will hear they have breast cancer sometime...

ONCY : 1.0600 (+2.91%)
ONC.TO : 1.44 (+0.70%)
PFE : 26.00 (+2.40%)
ARVN : 34.72 (+1.25%)
OLMA : 9.93 (+0.30%)
AZN : 68.55 (+0.28%)
How Recent Biotech Breakthroughs Are Changing the Fight Against Breast Cancer

USA News Group – More people are getting breast cancer this year. Around 300,000 women and 2,800 men will find out they have it. While 1 out of every 8 women will hear they have breast cancer sometime...

AVRN : 0.0125 (-30.56%)
ONCY : 1.0600 (+2.91%)
ONC.TO : 1.44 (+0.70%)
PFE : 26.00 (+2.40%)
ARVN : 34.72 (+1.25%)
OLMA : 9.93 (+0.30%)
AZN : 68.55 (+0.28%)
Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -5.48% and 5.88%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ARVN : 34.72 (+1.25%)
CELU : 3.03 (-5.61%)
Arvinas and Quantum Leap Healthcare Announce Clinical Study to Evaluate Vepdegestrant (ARV-471) in I-SPY-2 Endocrine Optimization Platform (EOP) Clinical Trial

/PRNewswire/ -- Arvinas, Inc. (Nasdaq: ARVN) and Quantum Leap Healthcare Collaborative™ today announced that Arvinas' vepdegestrant (ARV-471), a novel PROTAC®...

ARVN : 34.72 (+1.25%)
Harmony Biosciences Holdings, Inc. (HRMY) Surpasses Q1 Earnings and Revenue Estimates

Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 9.09% and 0.78%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the...

HRMY : 29.40 (+1.27%)
ARVN : 34.72 (+1.25%)
Arvinas, Inc. (ARVN) Surges 7.6%: Is This an Indication of Further Gains?

Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the...

ARVN : 34.72 (+1.25%)
ZLAB : 14.07 (-1.05%)
Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -50% and 8.29%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ARVN : 34.72 (+1.25%)
ADMA : 6.27 (+1.13%)
3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023

Health care stocks are trying to make a comeback and these three small-cap biopharma companies are leading the charge in some ways.

ARVN : 34.72 (+1.25%)
RCKT : 22.80 (-2.90%)
XNCR : 18.38 (-3.01%)
Arvinas, Inc. (ARVN) Soars 10.3%: Is Further Upside Left in the Stock?

Arvinas, Inc. (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase...

ARVN : 34.72 (+1.25%)
ALLO : 3.47 (+0.29%)
Jon Soderstrom Joins Wilson Sonsini as Chief Licensing Advisor

Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life sciences, and growth enterprises worldwide, announced today that Jon Soderstrom is joining the firm as its chief...

ACHN : 0.7912 (-21.66%)
ARVN : 34.72 (+1.25%)
NXTC : 1.6000 (+1.91%)
BHVN : 38.99 (-7.52%)
INZY : 4.51 (-1.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Arvinas Inc. is a biopharmaceutical company for patients suffering from debilitating and life-threatening diseases. It engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Arvinas Inc. is based in CT, United States.

See More

Key Turning Points

3rd Resistance Point 36.32
2nd Resistance Point 35.57
1st Resistance Point 35.14
Last Price 34.72
1st Support Level 33.96
2nd Support Level 33.21
3rd Support Level 32.78

See More

52-Week High 53.08
Fibonacci 61.8% 37.99
Last Price 34.72
Fibonacci 50% 33.33
Fibonacci 38.2% 28.66
52-Week Low 13.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar